Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

China, Canada, Japan, Turkey, Ecuador seek to join consultations in the Indo-EU Trade dispute over seizure of ‘in-transit’ generic drugs (Spicy IP) (Michael Geist)

EPO hearings in ‘broccoli and tomato cases’ (IPKat) (EPLAW)

Post-Bilski: Federal Circuit to reconsider diagnostic testing and medical methods – Prometheus v Mayo, Classen v Biogen (IP Spotlight) (Patently-O)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

China, Canada, Japan, Turkey, Ecuador seek to join consultations in the Indo-EU Trade dispute over seizure of ‘in-transit’ generic drugs (Spicy IP) (Michael Geist)

Consensus on binding biodiversity agreement elusive, to reconvene in September (IP Watch)

International experts see backswing in pendulum of biological patenting (IP Watch)

Brazil discusses patentability of medicines (IP tango)

East Africa: The WHO – an admission? – anti-counterfeiting legislation and affordable generic medicines (Afro-IP)

EU: ECJ: DNA must be doing its (patented) job: Monsanto Technology LLC v Cefetra BV and Others (IPso Jure) (IP Whiteboard)

EU: EPO hearings in ‘broccoli and tomato cases’ (IPKat) (EPLAW)

Kenya: WHO – a response: Kenyan anti-counterfeiting decision (Afro-IP)

US: Motion to dismiss recommended denied in false marking case: Promote Innovation LLC v. Ranbaxy Laboratories Inc. (EDTexweblog.com) (Docket Report)

US: Post-Bilski: Federal Circuit to reconsider diagnostic testing and medical methods – Prometheus v Mayo, Classen v Biogen (IP Spotlight) (Patently-O)

US: Federal Circuit review of patent term extensions – Ortho-McNeil v Lupin, Photocure v Kappos (Patently-O)

USPTO provides clarification regarding treatment of PTA letters (Patent Docs)

US: Pharmaceutical reverse payments and lower drug costs: An interesting dilemma! (Profitability through Simplicity)

US: Siemens Healthcare seeks review of BPAI decision awarding priority to Enzo Life Sciences (Patent Docs)

 

Products

Accu-Chec – US: False marking complaint filed concerning Accu-Chec products: Promote Innovation LLC v. K-V Pharmaceutical Co. et al. (Patent Docs)

Aricept (Donepezil) – US: Teva suspends litigation to invalidate Eisai’s compound patent for drug Aricept (IP Factor)

Clarinex (Desloratadine)– US: US: False marking complaint filed concerning Clarinex products: Promote Innovation LLC v. Schering Corp. et al. (Patent Docs)

Crestor (Rosuvastatin) – US: Patent infringement complaint following amended ANDA filing: AstraZeneca Pharmaceuticals LP et al. v. Torrent Pharmaceuticals Ltd. et al. (Patent Docs)

Effexor (Venlafaxine) – US: Sandoz loses motion for interlocutory appeal in Effexor patent suit with Wyeth (Patent Docs)

EpiPen Auto-Injector (Epinephrine) – US: Patent infringement complaint following a Paragraph IV certification: King Pharmaceuticals, Inc. et al. v. Sandoz, Inc. (Patent Docs)

Glivec (Imatinib) – India: Natco & Ranbaxy delay proceedings in the Glivec case before the Supreme Court (Spicy IP)

Glyset (Miglitol) – US: False marking complaint filed concerning Glyset products: Promote Innovation LLC v. Roche Diagnostics Corp. et al. (Patent Docs)

Istodax (Romidepsin) – US: False marking complaint filed concerning Istodax products: Promote Innovation LLC v. Schering Corp. et al. (Patent Docs)

Levitra (Vardenafil) – US: Patent infringement complaint following a Paragraph IV certification: Bayer Schering Pharma AG et al. v. Teva Pharmaceuticals USA Inc. et al. (Patent Docs)

Lipitor (Atorvastatin) – US: Apotex establishes declaratory judgment jurisdiction in Lipitor patent challenge, threatening the Pfizer-Ranbaxy settlement, but Pfizer reloads (Orange Book Blog)

Losec (Omeprazole) – EU: Misusing a patentee’s market power – Court of General Instance upholds EC ruling against AstraZeneca (ipwars.com)

Lovenox (Enoxaparin) – The Other shoe drops . . . . Sanofi sues FDA over generic LOVENOX approval (FDA Law Blog) (FDA Law Blog)

Lupron (Leuprolide) – US: False marking complaint filed concerning Lupron products: Promote Innovation LLC v. Abbott Laboratories Inc. et al. (Patent Docs)

Namenda (Memantine) – US: Mylan announces settlement agreement with Forest Lab’s and Merz Pharmaceuticals (SmartBrief)

Olux-E (Clobetasol) – US: Patent infringement complaint following a Paragraph IV certification: Stiefel Laboratories Inc. et al. v. Perrigo Israel Pharmaceuticals Ltd. et al (Patent Docs)

Protonix (Pantoprazole) – US: Teva, Sun fail to overturn jury verdict finding Pfizer Protonix patent valid (Patent Docs)

Ranexa (Ranolazine) – US: Patent infringement complaint following a Paragraph IV certification: Roche Palo Alto LLC et al. v. Lupin Pharmaceuticals, Inc. et al. (Patent Docs)

Relpax (Eletriptan) – US: Patent infringement complaint following Paragraph IV certification: Pfizer, Inc. et al. v. Apotex Inc. et al. (Patent Docs)

Renvela (Sevelamer) – US: Patent infringement complaints following a Paragraph IV certification:  Genzyme Corp. v. Lupin Ltd. et al.; Genzyme Corp. v. Watson Laboratories, Inc. (Patent Docs)

Tricor (Fenofibrate) – US:  Patent infringement complaints following a Paragraph IV certification – Elan Pharma International Ltd. et al v. Teva Pharmaceuticals USA, Inc.; Abbott Laboratories et al. v. Teva Pharmaceuticals USA, Inc. (Patent Docs)

Yaz & Yasmin (Drospirenone and Ethinyl Estradiol) – US: Patent infringement complaint following a Paragraph IV certification: Bayer Schering Pharma AG et al v. Lupin Ltd et al. (Patent Docs)

Zometa (Zoledronic acid) – US: Teva and Novartis settle patent dispute over Zometa (Patent Docs)

Zyprexa (Olanzapine) – Canada: Patent Act contains no reference to invalid selection patents: Eli Lilly v Novopharm (Patent Baristas)